UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback